NEW YORK(GenomeWeb) – Qiagen said after the close of the market on Thursday that the US Food and Drug Administration cleared the artus HSV-1/2 QS-RGQ kit for molecular diagnosis of herpes simplex virus type 1 and type 2 infections.

FDA cleared the HSV-1/2 kit in late December to run on the QIAsymphony RGQ molecular diagnostics system. Qiagen said the assay was its fifth in 2014 to receive FDA clearance or approval.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.